Vision bill lets states opt out of patient protections with a single clause

What it does

This bill amends federal health insurance law to require that optometrists in vision plans cannot be restricted in their choice of laboratories or suppliers for materials and services they provide to patients. It limits initial optometry agreements to 2-year terms (renewable with consent) and requires the federal government to annually notify states of their authority to enforce these rules, treating non-enforcement as a failure to comply with federal standards.

Why we flagged it

The bill's operative mechanism restricts insurer control over lab choice and agreement terms, framed as consumer protection. However, the final section grants states exclusive jurisdiction to override federal requirements, effectively creating a deregulation pathway for states that choose not to enforce the bill's protections.

What the text implies

• The state-law preemption clause (final section) allows states to pass laws that directly conflict with and nullify the bill's protections, potentially creating a race-to-the-bottom where states with strong insurance-industry lobbying exempt themselves from the federal standard.
• By requiring annual federal notification to states and treating non-response as non-enforcement, the bill creates a federal-state enforcement gap that may leave patients in non-compliant states without remedy.
• The bill does not specify remedies for patients or optometrists harmed by violations, leaving enforcement mechanisms unclear and potentially toothless.
• Optometrists gain negotiating leverage against insurers, but the bill does not address whether this translates to lower patient costs or merely shifts margin to providers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may reduce patient costs and expand choice by preventing insurers from steering patients to preferred labs, a concrete public benefit. However, the exclusive state-law carve-out in the final section potentially undermines federal protections by allowing states to override the bill's requirements, creating a patchwork of coverage and leaving enforcement uncertain.

Who stands to gain

• independent optical laboratories
• optometry practices (especially independent practitioners)
• optical suppliers and materials vendors

Named in the bill

optometrists, health insurance issuers, group health plans, optical laboratories, state insurance regulators, U.S. Department of Health and Human Services, Public Health Service Act Title XXVII

Where it stands

24 cosponsors: 12 Democrats, 12 Republicans.

• May 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 12, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 11 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,500,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Kevin Cramer, the sponsor, reported $204,312 in PAC receipts in the 2026 cycle.

• American Optometric Association — $2,350,000 on 2 filings
• Metlife Group, Inc. — $370,000 on 1 filing
• Essilorluxottica USA Inc. — $330,000 on 2 filings
• Vsp — $210,000 on 2 filings
• Vsp — $160,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.